Effects of Nicorandil on Cardiac Infarct Size in Patients With ST-segment Elevation Acute Myocardial Infarction

• Status: Unknown status
• Trial end date: 2018-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether nicorandil reduce cardiac infarct size in patient with ST-segment elevation acute myocardial infarction.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pusan National University Hospital
• Collaborator: JW Pharmaceutical
• Treatments: Nicorandil

Criteria

Inclusion Criteria:

• STEMI patients presenting within 12 hours after symptom onset

• Undergoing primary PCI

Exclusion Criteria:

• Previous myocardial infarction

• Atrial fibrillation

• RV infarction

• Cardiogenic shock

• Serum creatinine >2.0 mg/dL

• Narrow angle glaucoma

• Taking PDE-5 inhibitors